Prenetics Global’s (PRE) “Overweight” Rating Reiterated at Cantor Fitzgerald

Prenetics Global (NASDAQ:PRE)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research note issued on Thursday,Benzinga reports. They currently have a $9.00 price target on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 50.00% from the company’s current price.

Prenetics Global Trading Up 3.3 %

Shares of NASDAQ:PRE opened at $6.00 on Thursday. Prenetics Global has a 12-month low of $2.85 and a 12-month high of $7.84. The business has a 50 day moving average of $5.16 and a two-hundred day moving average of $5.08. The company has a market capitalization of $54.84 million, a PE ratio of -1.50 and a beta of -0.30.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.